Talking to patients about biosimilars

Volume: 14, Issue: 23, Pages: 2403 - 2414
Published: Oct 1, 2018
Abstract
Biologic therapies target aberrant pathways in diseases including diabetes, cancer and autoimmune disorders. Despite recent scientific advances, patient access to these agents can be limited. Biosimilars are designed to be highly similar to the originator biologic, targeting the same biological pathways, with comparable efficacy and safety. Biosimilars have the advantage of lower treatment costs, offering the potential for increased clinical use...
Paper Details
Title
Talking to patients about biosimilars
Published Date
Oct 1, 2018
Volume
14
Issue
23
Pages
2403 - 2414
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.